Dual-targeted microbubbles for atherosclerosis therapy: Inducing M1 macrophage apoptosis by inhibiting telomerase activity
Source abstract
Abstract
The progression of atherosclerosis (AS) is closely associated with M1 macrophages. Although the activation of macrophage telomerase during plaque formation has been documented, targeted modulation strategies remain challenging. In this study, we developed a dual-target microbubble-delivery system (Ab-MMB 1532 ) encapsulating BIBR1532, a telomerase inhibitor, for the targeted therapy of AS. This system exhibited remarkable targeting capabilities towards M1 macrophages, with its targeting advantage notably accentuated under high shear forces. Mechanistically, Ab-MMB 1532 inhibited telomerase activity by downregulating telomerase reverse transcriptase (TERT) expression, subsequently inducing caspase-3-mediated apoptosis. Integrated multi-omics profiling revealed that the inhibition of the NF-κB pathway served as the central regulatory hub. In vivo studies further confirmed that Ab-MMB 1532 effectively targets and accumulates within AS lesions, promoting M1 macrophage apoptosis through the inhibition of the TERT/NF-κB signaling axis, and significantly reducing plaque burden (25.4 % reduction vs. controls, p < 0.001). In summary, our findings suggest a novel approach for telomerase-targeted therapy in AS. Schematic diagram displaying the Ab-MMB 1532 fabrication, targeting, and its anti-AS properties. • Dual-target microbubble drug-delivery system for AS is developed. • Targeting toward M1 macrophages is notably accentuated under high shear forces. • Ab-MMB 1532 downregulates telomerase reverse transcriptase expression. • In vivo studies confirms that Ab-MMB 1532 targets and anti-AS performance.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ultrasound and Hyperthermia Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention10.1038/s41392-022-00955-7 ↗
2. Applications of inorganic nanoparticles in the diagnosis and therapy of atherosclerosis10.1039/D0BM00196A ↗
3. Heart disease and stroke statistics-2021 update: a report from the American heart association10.1161/CIR.0000000000000950 ↗
4. Mechanisms of plaque formation and rupture10.1161/CIRCRESAHA.114.302721 ↗
5. Atherosclerosis10.1038/s41572-019-0106-z ↗
6. Macrophages in atherosclerosis: a dynamic balance10.1038/nri3520 ↗
7. Macrophages in immunoregulation and therapeutics10.1038/s41392-023-01452-1 ↗
8. Macrophage polarisation and inflammatory mechanisms in atherosclerosis: implications for prevention and treatment
9. Monocytes in atherosclerosis: subsets and functions10.1038/nrcardio.2009.228 ↗
10. Overexpression of CD86 enhances the ability of THP-1 macrophages to defend against Talaromyces marneffei10.1002/iid3.740 ↗
11. Proinflammatory polarization of engineered heat-inducible macrophages reprogram the tumor immune microenvironment during cancer immunotherapy10.1038/s41467-024-46210-1 ↗
12. Macrophage polarization and metabolism in atherosclerosis10.1038/s41419-023-06206-z ↗
13. Telomeres and telomerase in cardiovascular diseases10.3390/genes7090058 ↗
14. Telomerase: key regulator of inflammation and cancer10.1016/j.phrs.2020.104726 ↗
15. Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages10.1161/ATVBAHA.110.219808 ↗
16. MicroRNA-216a promotes M1 macrophages polarization and atherosclerosis progression by activating telomerase via the Smad3/NF-κB pathway10.1016/j.bbadis.2018.06.016 ↗
17. Haemodynamics of atherosclerosis: a matter of higher hydrostatic pressure or lower shear stress?10.1093/cvr/cvab001 ↗
18. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis10.1038/s41569-021-00629-x ↗
19. Chan · 2018 · vol. 14
20. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity10.1021/acsnano.8b02037 ↗
21. Site‐specific MicroRNA‐33 antagonism by pH‐responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity
22. A targeting nanotherapy for abdominal aortic aneurysms10.1016/j.jacc.2018.08.2188 ↗
23. Nanoparticles responsive to the inflammatory microenvironment for targeted treatment of arterial restenosis10.1016/j.biomaterials.2016.08.003 ↗
24. Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis10.7150/thno.70896 ↗
25. Magnetic targeting to enhance microbubble delivery in an occluded microarterial bifurcation10.1088/1361-6560/aa858f ↗
26. Comparison of magnetic microbubbles and dual-modified microbubbles targeted to P-selectin for imaging of acute endothelial inflammation in the abdominal aorta10.1007/s11307-016-0997-y ↗
27. Circulating magnetic microbubbles for localized real-time control of drug delivery by ultrasonography-guided magnetic targeting and ultrasound10.7150/thno.20781 ↗
28. BIBR1532 affects endometrial cell proliferation, migration, and invasion in endometriosis via telomerase inhibition and MAPK signaling10.1159/000530460 ↗
29. Biodegradable black phosphorus nanosheets mediate specific delivery of hTERT siRNA for synergistic cancer therapy10.1021/acsami.8b04807 ↗
30. Lipid/PLGA hybrid microbubbles as a versatile platform for noninvasive image-guided targeted drug delivery10.1021/acsami.9b10188 ↗
31. Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition
32. Ultrasound molecular imaging-guided tumor gene therapy through dual-targeted cationic microbubbles10.1039/D0BM01857K ↗
33. Magnetic black phosphorus microbubbles for targeted tumor theranostics10.1515/nanoph-2021-0085 ↗
34. Scalable production of large quantities of defect-free few-layer graphene by shear exfoliation in liquids10.1038/nmat3944 ↗
35. IgE contributes to atherosclerosis and obesity by affecting macrophage polarization, macrophage protein network, and foam cell formation10.1161/ATVBAHA.119.313744 ↗
36. The DEAD-box helicase Hlc regulates basal transcription and chromatin opening of stress-responsive genes10.1093/nar/gkac684 ↗
37. Systems biology and multi-omics integration: viewpoints from the metabolomics research community10.3390/metabo9040076 ↗
38. Challenges and emergent solutions for LC-MS/MS based untargeted metabolomics in diseases10.1002/mas.21562 ↗
39. Nucleotide metabolism regulates human telomere length via telomerase activation10.1038/s41588-023-01359-1 ↗
40. p53-mediated control of aspartate-asparagine homeostasis dictates LKB1 activity and modulates cell survival10.1038/s41467-020-15573-6 ↗
41. Integrating metabolomics and transcriptomics to analyze the differences of breast muscle quality and flavor formation between Daweishan mini chicken and broiler10.1016/j.psj.2024.103920 ↗
42. Molecular markers of type II alveolar epithelial cells in acute lung injury by bioinformatics analysis
43. Recent advances in dual-ligand targeted nanocarriers for cancer therapy10.1016/j.drudis.2022.04.011 ↗
44. Telomerase: central regulator of all of the hallmarks of cancer10.1016/j.tibs.2013.07.001 ↗
45. Macrophage phenotypes in atherosclerosis10.1111/imr.12218 ↗